Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders

Exclusion Criteria

• •Requirement for acute therapy for other AIDS-defining illness or other serious medical illnesses (in the opinion of the site investigator) within 14 days prior to study entry.
• •Known allergic or hypersensitivity reaction to FERAHEME, parental iron, parental dextran, parental iron-dextran, or parental iron-polysaccharide preparations
• •Known history of an iron overload syndrome (e.g., hereditary hemochromatosis, porphyria cutanea tarda)
• •Medical conditions (e.g., chronic hemolytic anemia) which requires frequent blood transfusions
• •Taking oral iron supplementation
• •Any factor that precludes MRI scan including presence of metal or exposure to metal work (e.g. metal grinder/worker) and claustrophobia
• •Past or present HIV opportunistic infection of the brain, learning disability, head injury with prolonged loss of consciousness or cognitive sequelae, or other non-HIV risk factor that in the opinion of the principal investigator (PI) may impact cognitive performance.
• •History of epilepsy requiring treatment with an antiepileptic
• •Other chronic illnesses including insulin-dependent diabetes, autoimmune diseases, and endocrinopathies, except subjects on stable physiologic replacement therapy for low testosterone or thyroid levels
• •Current active substance or alcohol dependence or positive urine toxicology screen.
• •Pregnancy or breast-feeding, intent to become pregnant during the course of the study.
• •Any condition which, in the opinion of the investigator, would compromise the subject's ability to participate in the study
• •Aspartate aminotransferase (AST), alanine aminotransferase (ALT) greater than 2x upper limits of normal on pre-entry baseline laboratory safety assessment prior to study enrollment.
• •Elevated iron levels on pre-entry baseline laboratory safety assessment prior to study enrollment.
• •Hematocrit \> 52% or Hemoglobin \> 18 g/dL on pre-entry baseline laboratory safety assessment prior to study enrollment.